Therapy Areas: Cardiovascular
Merck's anacetrapib reduces risk of major coronary events in REVEAL study
31 August 2017 -

United States-based Merck's cardiovascular treatment, anacetrapib, decreased the risk of major coronary events in the REVEAL study, it was reported yesterday.

The company, along with the researchers in the clinical trial service unit at the University of Oxford, reported that the product has decreased the risk of major coronary events by 9 percent relative to placebo in the study of 30,449 patients with atherosclerotic vascular disease receiving LDL-C lowering treatment with atorvastatin.

The study is a randomised evaluation of the effects of anacetrapib through lipid modification outcomes. The product is the company's investigational cholesteryl ester transfer protein (CETP) inhibitor. During the trial, the 30,449 adults with atherosclerotic vascular disease on study-mandated intensive atorvastatin therapy have been randomly assigned to secure either anacetrapib 100 mg once daily or matching placebo.



Related Headlines